The pharmaceutical and life sciences landscape is changing fast in China. There are close to 1,000 bio-related companies in China, and half were established in the last five years or so. Citi expects China’s pharmaceutical market to grow from its current level of $40 billion to $100 billion by 2015 and to $200 billion by 2020, which will make it the second largest in the world, passing Japan along the way.
SEOUL - A minor opposition party lawmaker accused the Korean government of backing down from its earlier stance to help fund compulsory vaccinations for diseases such as hepatitis B.
Pfizer and GlaxoSmithKline attracted attention earlier this year while finalizing an agreement with the public-private GAVI Alliance to bring the newest pneumococcal vaccines - Prevenar 13 and Synflorix, respectively - to developing countries.
Hospira has voluntarily suspended shipments of two drugs – Propofol, an anesthesia, and Liposyn, a fat emulsion for low birth weight babies – to address manufacturing concerns raised by FDA in a recent warning letter.
Merck unveils integrated late-stage pipeline, including 40 Phase II and Phase III medicines of which eight are in the areas of cardiovascular or infectious disease.
Salix's Xifaxan for hepatic encephalopathy passed advisory committee review, but members expressed unease about lingering safety concerns and called for additional studies.read_more_>
